Singapore Cell Based Immunotherapy Market Insights Forecasts to 2033

• The Singapore Cell Based Immunotherapy Market Size was valued at USD 8.5 Million in 2023.
• The Market Size is growing at a CAGR of 19.72% from 2023 to 2033
• The Singapore Cell Based Immunotherapy Market Size is expected to reach USD 51.4 Million by 2033

The Singapore Cell Based Immunotherapy Market Size is anticipated to exceed USD 51.4 Million by 2033, growing at a CAGR of 19.72% from 2023 to 2033. The increasing cancer prevalence, technological advances in cell therapy, favorable regulatory environment, rising investment & collaborations, and personalized medicine are driving the growth of the cell based immunotherapy market in the Singapore.     

Market Overview

Cell based immunotherapy refers to treatment that uses the cells of the immune system to eliminate cancer. Cell therapies are presently being tested in clinical trials for a number of cancer types, both by itself and in conjunction with other treatments. It is a chemotherapy alternative for the treatment of cancer. The human body's stem cells can regenerate the specialized cells and treat a wide range of illnesses. Adoptive T-cell therapy (ACT), which can be used for several oncological and non-oncological reasons, has become a powerful and practical kind of therapeutic intervention in recent years. Numerous early T-cell-based pharmacological intervention variations, such as those based on antigen-sensitized T-cell receptors (TCRs) and chimeric antigen receptors (CARs), are already authorized and on the market.

Report Coverage

This research report categorizes the market for the Singapore cell based immunotherapy market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Singapore cell based immunotherapy market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Singapore cell based immunotherapy market.

Driving Factors

There were 84,002 cancer cases reported in Singapore between 2017 and 2021, with males accounting for 49% and females for 51% of those cases, respectively. The increasing prevalence of cancer and the adoption of cell therapies for recognizing and eliminating cancer cells are driving the market growth. The technological advancements in cell therapy such as CAR-T cell therapy for treating hematological malignancies are propelling the market growth. The favorable regulatory environment for facilitating the safe use of novel therapeutics including genetically engineered chimeric antigen receptor (CAR)-T cells is promoting the market growth. The adoption of personalized approaches for improving treatment outcomes, sparing patients from ineffective therapies, and fine-tuning immunotherapies on an individual basis are augmenting market growth.    

Restraining Factors

Significant operational challenges, a highly aseptic environment, and the requirement for a large capital investment are some of the elements that drive up the cost of manufacturing cellular immunotherapy. The high cost of manufacturing cellular immunotherapy products is restraining the cell based immunotherapy market.

Market Segmentation

The Singapore Cell Based Immunotherapy Market share is classified into therapy type, indication, and end-use.

• The CAR-T cell therapy segment is anticipated to hold the largest market share during the forecast period.

The Singapore cell based immunotherapy market is segmented by therapy type into CAR-T cell therapy, TCR therapy, TIL therapy (tumor-infiltrating lymphocytes), NK cell therapy (natural killer cells), dendritic cell therapy, and others. Among these, the CAR-T cell therapy segment is anticipated to hold the largest market share during the forecast period. T-cell immune cells are used in CAR T cell therapy by altering it in the lab and used for effectively destroying cancer cells. Over 500 CAR T cell treatment experiments are currently in progress. The increasing product approvals are driving the market in the CAR-T cell therapy segment.

• The B-cell malignancies segment accounted for the largest market share during the forecast period.

The Singapore cell based immunotherapy market is segmented by indication into B-cell malignancies, prostate cancer, liver cancer, renal cell carcinoma, and others. Among these, the B-cell malignancies segment accounted for the largest market share during the forecast period. B-cells are antibody producers and contribute to immune regulation, acting as potent antigen-presenting cells. The availability of treatments for B-cell malignancy, such as BREYANZI and Yescarta is driving the market growth in the B-cell malignancy segment.

• The hospitals segment dominated the Singapore cell based immunotherapy market with the largest market share in 2023.       

Based on the end-use, the Singapore cell based immunotherapy market is divided into hospitals, cancer institutes, and others. Among these, the hospitals segment dominated the Singapore cell based immunotherapy market with the largest market share in 2023. Cellular immunotherapy infusion necessitates qualified medical professionals; these needs are better suited for hospital environments, which further improves patient compliance.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Singapore cell based immunotherapy market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Novartis
• Bristol Myers Squibb
• Gilead Sciences
• Adaptimmune Therapeutics
• Bluebird bio
• Cellectis
• Precision Biosciences
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In November 2022, BioNTech buys the Novartis plant in Singapore, which would retrofit for mRNA vaccine production.

Market Segment

This study forecasts revenue at Singapore, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Singapore Cell Based Immunotherapy Market based on the below-mentioned segments:

Singapore Cell Based Immunotherapy Market, By Therapy Type

• CAR-T Cell Therapy
• TCR Therapy
• TIL Therapy (Tumor-Infiltrating Lymphocytes)
• NK Cell Therapy (Natural Killer Cells)
• Dendritic Cell Therapy
• Others

Singapore Cell Based Immunotherapy Market, By Indication

• B-Cell Malignancies
• Prostate Cancer
• Liver Cancer
• Renal Cell Carcinoma
• Others

Singapore Cell Based Immunotherapy Market, By End-Use

• Hospitals
• Cancer Institutes
• Others